Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients with RR lymphoma treated with gemcitabine, cisplatin or carboplatin and dexamethasone (GDP/GDCarboP) +/- rituximab regimen in our center.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: May Chiu, Samuel Hague, Anna Elinder-Camburn, Eileen Merriman, Henry Chan Tags: Original Study Source Type: research
More News: Chemotherapy | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Rituxan | Stem Cell Therapy | Stem Cells | Study | Transplants